Re-audit of Radiotherapy Waiting Times 2005
|
|
- Samantha Campbell
- 5 years ago
- Views:
Transcription
1 Abstract Re-audit of Radiotherapy Waiting Times 2005 E. Summers, M Williams Royal College of Radiologists, 38 Portland Place, London W1B 4JQ, UK Aim: To determine current waiting times for radiotherapy in the UK. Method: Web-based audit of all patients commencing a radiotherapy treatment course in the week beginning Monday 26 th September Results: The data were compared with previous audits in 1997 and Waiting Times for radiotherapy remain unacceptable with 53% of radical patients and 57% of adjuvant patients waiting longer than 4 weeks from decision to treat. 33% of patients waited longer than two weeks for their palliative radiotherapy. Nevertheless, these results do show improvement when compared with 2003, but are still worse than the initial data obtained in % of patients fell into the first definitive treatment category; of these, were treated within the DH 31 day wait guideline, and 74% were treated within the 62 day guideline. However, data were incomplete, particularly for the 62 day target, and these results do not give an accurate picture of compliance. Conclusion: Radiotherapy waits remain unacceptable even though an improvement has been shown. The data on the DH 31/62 day waits were incomplete as they were collected at a time at which the system was being implemented. The targets for first definitive treatment only apply to 15 % of radiotherapy patients. The Royal College of Radiologists stands by the importance of the JCCO targets for all radiotherapy patients. Introduction: Standards for waiting times for cancer treatment were set by the JCCO in 1993 (1). 1. For urgent radiotherapy or chemotherapy Good practice 24 hours Maximum acceptable 48 hours 2. For palliative radiotherapy (according to severity of symptoms) Good practice 48 hours Maximum acceptable 2 weeks (for non-severe symptoms) 3. For radical radiotherapy involving complex treatment planning Good practice 2 weeks
2 Maximum acceptable 4 weeks* *Where additional specialist staging procedures are necessary These standards are important to patients, as there is good evidence that delay can allow cancers to progress (2) and become unsuitable for radical treatments (3). This results in decreased cure rates and worse outcomes for patients (4,5,6,7,8). This audit was initially undertaken in 1997 and showed that overall 28% of patients were waiting longer than the maximum one-month target for radical treatment advised by the JCCO (9). The audit was repeated in 2003 and showed that waiting times had lengthened in most centres with exceeding the target (10). The audit was repeated in 2005 to obtain current data on waiting times, the percentage of patients who are receiving their first definitive treatment (FDT) and their performance in terms of the Department of Health s (DH) 31 and 62 day target waits (11, 12). Method: For the first time the College used web-based technology to collect the data for this audit enabling Centres to input their data directly. Audit Leads were given the opportunity to view the web data collection tool and to make comments prior to its launch. All feedback was taken into consideration before finalising the data collection tool (see Appendix 1). All radiotherapy centres in the UK were invited to participate in this national audit. The survey covered all patients within 1 week who commenced treatment between Monday 26 th September and Sunday 2 nd October 2005 inclusive. The data collection tool was split into five sections: o Diagnosis o Site to be treated o Prescription details o Dates: Three dates were collected: The date of booking request was defined as the date when a clinical oncologist and a patient have agreed to a plan of treatment, including a course of radiotherapy, and the clinical oncologist completes a booking request or an electronic request is logged. The date the patient is able to start treatment was defined as If the patient is not ready to start immediately then the clinical oncologist should define a separate ready to start date and the general reason for this delay, which include 1) patient choice, 2) completing planned treatment and 3) medically not yet fit.
3 The date radiotherapy commenced is the date of the first fraction of treatment. For those patients whose treatment is the first definitive treatment (FDT), two further time points were required to be able to measure against the DH 31 and 62 day targets: o Date of urgent referral by GP: this is the date the GP signs the referral request and Trusts must respond within 24 hours. o The decision to treat date: this is the date of the consultation in which the patient and clinician agree the treatment plan for first treatment. Data on elective delays were also collected and asked for the reason why there was a delay if appropriate. o Treatment intent (Radical, palliative, adjuvant): for this section centres were advised to use their local definitions. o Treatment priority (emergency, urgent, routine): for this section centres were advised to use their local definitions. A comparison of all submitted data was then made with data collected in 1998 and Every attempt was made to ensure that the collection and analysis of the data were carried out consistently across all three data sets. Results: 55/57 (96%) centres responded to the College s request to provide data for this analysis. Data on 2,688 cases from 55 centres were entered into the data collection software. This is comparable to 2,631 in February 1998 from 98% of centres and 2,498 cases from 10 of Centres in 2003 in September; all audits looked at a one-week period. Table 1 shows an analysis by waiting-list status and treatment intent for all cases within this survey. For the rest of the report, patients who experienced an elective delay (because of patient choice, completing planned treatment or medically not fit) (n= 712) are excluded from the analysis. Table 1: Emergency Urgent Routine Don t Total know/not documented Radical skin Radical non-skin Palliative Adjuvant pre-op
4 Adjuvant post-op No treatment indicated Totals Total cases audited, 2688 Table 2 and Figures 1-3 show that there has been slight improvement in meeting JCCO targets in the 2005 audit, but that the majority of radical and adjuvant post-op patients still wait longer than the maximum acceptable delay of 4 weeks from the decision to treat. Table 2: Patient group % Within good practice % Maximum acceptable delay % Outside of standard Radical Palliative Adjuvant post-op For those cases whose treatment is FDT the following DH targets apply: o 10 of patients should have commenced definitive treatment within 31 days of the decision to treat. o 10 of patient referred urgently by their GP should have commenced definitive treatment within 62 days of their referral. This target only applies to the 15% of radiotherapy patients for whom it is their first definitive treatment. Figure 4 shows that the figure ranges from 4% of breast cancer patients to 15% of palliative patients. These data contain a significant proportion of Don t know, but nevertheless, it is clear that these targets apply only to a selected subset. Figures 5 and 6 show that the 31 day wait was met in 71% of cases overall (after excluding missing data). Figures 7 and 8 show that overall, (after excluding missing data) 74% of cases met the 62 day target. This data set was very incomplete. Most radiotherapy centres found it difficult to record the dates needed for the 62 day target, as the referral dates were not available within their departments. This survey was undertaken as the target was being implemented and Trusts have had to set up novel management systems in order to address this target for patients referred after initial investigation at outside hospitals.
5 Figures 9, 10 and 11 contain data received from individual centres over the three audits. These ranked charts show the percentage of patients treated at each centre within the acceptable delay. Patients who had an elective delay were excluded and some centres therefore did not start a patient with a particular indication within the week in question. The number of centres shown therefore varies between audits (see Appendix 2). The charts give an overview of the proportion of centres with all or none of the patients achieving the targets, which highlights the inequity across the UK. For all three datasets, the deterioration between 1997 and 2003 is clearly seen, as is the subsequent improvement. Adjuvant radiotherapy is predominantly prescribed for breast cancer (63% of cases): in the 2003 audit there was a marked increase in the number of centres with no patients achieving the target. This has now improved in the 2005 audit. Centre Directors will be issued with their code number, which will identify their centre on each chart. A summary of these keys, which will be issued by the RCR Audit Office, is shown in Appendix 2. Centres will be able to identify their performance over time and in comparison with peers. Discussion: These data show that radiotherapy waiting times remain unacceptable. There is good evidence that these delays reduce the chance of cure and worsen outcomes in some patients (2-8). At the time of the survey the DH First Definitive Treatment targets were just being implemented and our data are incomplete. It is particularly important to note that the 31 and 62 day targets only apply to a small subset of radiotherapy patients. The College takes the view that it is imperative that waits for radiotherapy are reduced for all patients to maximise their chance of cure. A planned programme of national investment in staff, recruitment and training is required to achieve this. The RCR welcomes the opportunity to work through the National Radiotherapy Advisory Group (NRAG) to develop such a plan. Acknowledgements: We thank the staff in all UK Radiotherapy Centres who undertook the data collection; and A Hinks and C Squire for data management in 1997 and We are grateful to Sally Ginn and Nan Parkinson for typing the manuscript. We thank Dr Robin Hunter and Dr Diana Tait for helpful comments. References: 1. Joint Council for Clinical Oncology. Reducing delays in cancer treatment: some targets. London: Royal College of Physicians, 1993.
6 2. Coles CE, Burgess L, Tan LT. An audit of delays before and during radical radiotherapy for cervical cancer: effect on tumour cure probability. Clin Oncol 2003;15: O Rourke N, Edwards R. Lung cancer treatment waiting times and tumour growth. Clin Oncol 2000;12: O Sullivan B, Mackillop W, Grice B. The influence of delay in the initiation of definitive radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 1998;42(suppl): Fortin A, Bairati I, Albert M, et al. Effect of treatment delay on outcome of patients with early stage head and neck carcinoma receiving radical radiotherapy. Int J Radiat Oncol Biol Phys 2002;52: Waaijer A, Terhaard CH, Dehnad H, et al. Waiting times for radiotherapy: consequences of volume increase for the TCP in oropharyngeal carcinoma. Radiother Oncol 2003;66: Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J Clin Oncol 2003; 21: Mikeljevic J, Haward R, Johnston C et al. Trends in postoperative radiotherapy delay and the effect on survival in breast cancer patients treated with conservation surgery. Br J Cancer 2004; 90: Royal College of Radiologists. A national audit of waiting times for radiotherapy. London: Royal College of Radiologists, Ash D, Barrett A, Hinks A, Squire C. Re-audit of Radiotherapy Waiting Times London: Royal College of Radiologists, 2003; Clinical Oncol 2004; 16: The NHS Cancer Plan: Providing a Patient Centred Service; Department of Health, ; The NHS Cancer Plan: a Plan for Investment, a Plan for Reform; Department of Health; ;
7 Fig % Within 2 w eeks % Within 4 w eeks % Outside maximun acceptable delay JCCO Targets RADICAL Fig % Within 4 w eeks % Outside maximun acceptable delay JCCO Targets ADJUVANT Fig 2 % Within 2 days JCCO Targets PALLIATIVE 80 % Within 2 w eeks % Outside maximun acceptable delay
8 Fig 4: First Definitive Treatment RADICAL PALLIATIVE 22% 14% 15% Yes No Don't Know Yes No Don't Know 64% 65% BREAST PROSTATE 13% 4% 16% 9% Yes No Don't Know Yes No Don't Know 83% 75%
9 Fig 5 31 Day Wait Fig 6 31 Day Wait 10 9 % Within good practice limit % Outside maximun acceptable delay % missing data 44% 43% 9 65% 45% 46% 71% 1 13% 29% 4% 6% 6% 9% 1 29% Radical Palliative Breast Prostate % Within good practice limit % Outside maximun acceptable delay Fig 7 % Within good practice limit 62 Day Waits Fig 8 62 Day Wait 9 % Outside maximun acceptable delay % missing data 69% 67% 81% 82% 74% 29% 19% 12% 13% 15% 26% 1 4% 6% 3% 1 Radical Palliative Breast Prostate % Within good practice limit % Outside maximun acceptable delay
10 Figure 9: % Within Maximum Acceptable Delay for Palliative Cases Palliative Palliative 2003 Palliative
11 Figure 10: % Within Maximum Acceptable Delay for Radical Cases Radical Radical 2003 Radical
12 Figure 11: % Within Maximum Acceptable Delay for Adjuvant Cases Adjuvant Adjuvant 2003 Adjuvant
13 Appendix 1: RCR Re-Audit of Radiotherapy Waiting Times 2005 Data Collection Proforma Centre ID number (as allocated by the RCR): Patient ID number: Patient Diagnosis: Bladder Breast Central Nervous System Colorectal Gynaecological Head and Neck Lung Lymphoma (inc.leukaemia and myeloma) Prostate Sarcoma Skin Upper GI Unknown Diagnosis Other (inc. renal, germ cell etc) Site Treated: Abdomen Axilla Bladder Bone Brain Breast only Breast with nodes Breast boost Chest Chest wall Chest wall with nodes Head and Neck (+/- nodes) Neck nodes Limb (inc. sarcoma) Pelvis (not bone) Prostate Skin Total body irradiation Other (excluding bone mets) Prescribed dose: Date of booking request: Date patient able to start treatment: Date radiotherapy commenced: Gy # # s per week / / / / / / Was there an elective delay? No Please check prescription details, in the last audit there seemed to be some errors, probably due to the wrong field being filled in. Date the booking request form is completed If patient not ready to start treatment then the oncologist should define a separate ready to start date. The date of the first fraction of treatment. If yes why? Chemotherapy/Hormone Therapy Recovering from surgery Patient request (holidays etc) Post-chemotherapy delay Intercurrent illness Don t know Other (please specify)
14 Patient ID number: Treatment intent [Local definitions should be used] Waiting list status Radical skin Emergency (within 24hours) Radical non-skin Urgent (category 1) Palliative Routine (category 2) Adjuvant pre-operative Don t know Adjuvant postoperative Is this the patient s first definitive treatment for cancer? [the first intervention which is intended to remove or shrink the tumour] No Don t know Yes If yes: Date of urgent referral by GP / / [date the GP signs the request form] Date of decision to treat / / [date of the consultation in which the patient and clinician agree the treatment plan for first treatment]
15 Appendix 2 Centre rating per year per intent by RCR centre ID number, to be used in conjunction with Figures 9, 10 and 11. Centre ID Palliative Rating 1998 Palliative rating 2003 Palliative rating 2005 Radical rating 1998 Radical rating 2003 Radical rating 2005 Adjuvant rating 1998 Adjuvant rating 2003 Adjuvant rating No data No data No data No data No data 34 No data No data No data No data No data No data No data No data No data No data No data 24 No data No data No data No data No data Centre Palliative Palliative Palliative Radical Radical Radical Adjuvant Adjuvant Adjuvant
16 ID Rating 1998 rating 2003 rating 2005 rating 1998 rating 2003 rating 2005 rating 1998 rating 2003 rating No data No data No data 27 7 No data 34 No data No data No data No data No data No data 18 5 No data No data No data No data No data No data No data No data No data No data No data No data No data No data No data No data 18 7 No data No data
Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007
Re-audit of Radiotherapy Waiting Times in the United Kingdom, 2007 K. J. Drinkwater, M. V. Williams The Royal College of Radiologists, 38 Portland Place, London W1B 1JQ, UK ABSTRACT: This is the fourth
More informationNational Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator
National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care
More informationFor information only. Page 1 of 16
The Royal College of Radiologists 38 Portland Place London W1B 1JQ Telephone 020 7636 4432 Fax 020 7323 3100 Citation details: Board of the Faculty of Clinical Oncology. The Royal College of Radiologists
More informationLCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
More informationGeographical Variation in Radiotherapy Services Across the UK in 2007 and the Effect of Deprivation
Clinical Oncology (2009) 21: 431e440 doi:10.1016/j.clon.2009.05.006 Original Article Geographical Variation in Radiotherapy Services Across the UK in 2007 and the Effect of Deprivation M. V. Williams*,
More informationCancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0
Cancer Waiting Times Adjuvant Radical External Beam Radiotherapy Definitions Version 1.0 1 April 2015 Document Control Document Purpose Definitions for NHS Boards for the adjuvant radical external beam
More informationCommissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013
Commissioning Cancer Services Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013 The Health & Social Care Bill (27 th March 2012) Two New Organisations NHS Commissioning Board (NHS CB)
More informationPalliative care - the opportunities. Dr David Brooks Macmillan Consultant in Palliative Medicine Chesterfield Royal Hospital
Palliative care - the opportunities Dr David Brooks Macmillan Consultant in Palliative Medicine Chesterfield Royal Hospital Our Commitment to you for end of life care The Government Response to the
More informationGuideline for the Follow-up of Patients with Gynaecological Malignancies
Guideline for the Follow-up of Patients with Gynaecological Malignancies Version History Version Date Summary of Change/Process 2.0 20.02.08 Endorsed by the Governance Committee 2.1 18.11.10 Circulated
More informationUnknown Primary Service for patients at Chesterfield Royal Hospital
Unknown Primary Service for patients at Chesterfield Royal Hospital David Brooks Macmillan Consultant in Palliative Medicine Louise Merriman GP Cancer Lead With thanks to Macmillan Cancer Support, who
More informationCancer of Unknown Primary (CUP) Protocol
1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationQuality assurance in Health Services: the paradigm of radiotherapy
JBUON 2014; 19(1): 47-52 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com REVIEW ARTICLE Quality assurance in Health Services: the paradigm of radiotherapy Aristoula
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Specialist Sarcoma Multi Disciplinary Team for Suspected Bone Sarcoma Version History Version Date Brief Summary
More informationWest Midlands Sarcoma Advisory Group
West Midlands Sarcoma Advisory Group Guideline for the Initial Investigation and Referral to Sarcoma Specialist Multi Disciplinary Team for Suspected Sarcoma of Soft Tissue Extremities (limbs and trunk
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationTrust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme
Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More information2010 National Survey. University College London Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey University College London Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationWaiting Times for Suspected and Diagnosed Cancer Patients
Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared
More informationPATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE
PATHWAY MANAGEMENT OF METASTATIC SPINAL CORD COMPRESSION (MSCC) THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: Dr V. Misra Version: Accountable Committee: V3 MSCC Network
More informationSupra Network Sarcoma Advisory Group (SAG) Annual Report
London and South East Sarcoma Network Supra Network Sarcoma Advisory Group (SAG) Annual Report 2011-2012 Hosted by Date: December 2012 Version: 2 Review Date: September 2013 London Cancer Integrated Cancer
More informationCancer of Unknown Primary (CUP)
Cancer of Unknown Primary (CUP) Pathways and Guidelines V1.0 London Cancer September 2013 The following pathways and guidelines document has been compiled by the London Cancer CUP technical subgroup and
More information2010 National Survey. East Kent Hospitals University NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The North West London Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. Royal National Orthopaedic Hospital NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More information2010 National Survey. The Leeds Teaching Hospitals NHS Trust
National Cancer Patient Experience Programme 2010 National Survey Published January 2011 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of the Department
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More information2010 National Survey. Northern Lincolnshire and Goole Hospitals NHS Foundation Trust
National Cancer Patient Experience Programme 2010 National Survey Northern Lincolnshire and Goole Hospitals NHS Foundation Trust Published January 2011 The National Cancer Patient Experience Survey Programme
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2013 March 2014 Mr Colin McKay Consultant Surgeon NMCN Clinical
More informationMANAGEMENT OF PATIENTS WITH METASTATIC SPINAL CORD COMPRESSION
CLINICAL POLICY MANAGEMENT OF PATIENTS WITH METASTATIC SPINAL CORD COMPRESSION DOCUMENT REF: PCLASCORD (Version No. 1.4) Name and designation of policy author(s) Approved by (committee, group, manager)
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More informationSELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)
SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician GMCN ROYAL WOLVERHAMPTON HOSPITALS The Royal Wolverhampton Hospitals Trust Lung MDT (11-2C-1) - 2011/12 Dr Angela Morgan
More informationNCIN Conference Feedback 2015
NCIN Conference Feedback 2015 Parallel Sessions Treatments (Black type is the topic; blue type are comments) The use of population and research data in the development of guidelines for cancer treatment
More informationProgress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England
Report by the Comptroller and Auditor General Department of Health, NHS England and Public Health England Progress in improving cancer services and outcomes in England HC 949 SESSION 2014-15 15 JANUARY
More informationAcute Oncology Services Clinical Forum: Metastatic Spinal Cord Compression. Tuesday 17 th September 2013
Acute Oncology Services Clinical Forum: Metastatic Spinal Cord Compression Tuesday 17 th September 2013 Welcome, Introduction and Aims of the Event Dr Tom Newsom-Davis, LCA AOS Pathway Chair Why MSCC?
More informationNational Cancer Patient Experience Programme National Survey. South Tees Hospitals NHS Foundation Trust. Published September 2014
National Cancer Patient Experience Programme 2014 National Survey South Tees Hospitals NHS Foundation Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken
More informationDRAFT SARCOMA MEASURES
Gateway 15612 Draft Sarcoma Measures Page 1 of 44 DH INFORMATION READER BOX Policy Estates HR / Workforce Commissioning Management IM & T Policy Planning / Finance Clinical Social Care / Partnership Working
More informationNational Cancer Patient Experience Programme National Survey. Royal National Orthopaedic Hospital NHS Trust. Published September 2014
National Cancer Patient Experience Programme 2014 National Survey Royal National Orthopaedic Hospital NHS Trust Published September 2014 The National Cancer Patient Experience Survey Programme is undertaken
More informationCOSD & Source of Referral
COSD & Source of Referral A Brief guide October 2014 Michael Sharpe Data Improvement Manager National Cancer Registration Service What is COSD? Cancer and Outcomes Services Dataset Clinical dataset for
More informationTransforming Cancer Services for London
Programme Director Paul Roche Status Draft Owner Laura Boyd Version 0.4 Author Jennifer Layburn Date 15/05/13 Transforming Cancer Services for London Best Practice Commissioning Pathway for the early detection
More informationNational Optimal Lung Cancer Pathways. Dr Sadia Anwar Nottingham University Hospitals NHS Trust Clinical Lead for Lung Cancer
National Optimal Lung Cancer Pathways Dr Sadia Anwar ttingham University Hospitals NHS Trust Clinical Lead for Lung Cancer Overview How NOLCP evolved How it relates to national guidance Pathways Implementation
More informationGuideline for the Management of Vulval Cancer
Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11
More informationActivity Report July 2012 June 2013
Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Cancer of Unknown Primary Network Site Specific Group Revision due: April 2019 Page 1 of 11 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More informationNational Standards for Sarcoma Services
National Standards for Sarcoma Services 2009 TABLE OF CONTENTS 1. INTRODUCTION TO THE NATIONAL CANCER STANDARDS...2 2. METHODOLOGY...4 3. FORMAT...4 4. INTRODUCTION TO SARCOMA...5 STANDARDS TOPIC: ORGANISATION...10
More informationNational Standards for Sarcoma Services 2009
National Standards for Sarcoma Services 2009 Crown copyright July 2010 F1101011 Contents 1. Introduction to the National Cancer Standards 2. Methodology 3. Format 4. Introduction to Sarcoma Standards Topic:
More informationNational System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy
Canadian Partnership for Quality Radiotherapy (CPQR) National System for Incident Reporting in Radiation Therapy (NSIR-RT) National System for Incident Reporting in Radiation Therapy (NSIR-RT) Taxonomy
More informationPEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM)
PEER REVIEW VISIT REPORT (MULTI-DISCIPLINARY TEAM) Network Organisation (Trust) Team DCN POOLE Poole THYROID ONLY MDT (11-2I-2) - 2011/12 Peer Review Visit Date 18th August 2011 Compliance THYROID ONLY
More informationThere are a number of national guidelines and performance standards which support the implementation of a straight to CT pathway.
December 2015 CONTENTS Contents... 2 1 Introduction... 3 2 Case for Change... 3 3 Evidence... 3 3.1 National and regional policy... 3 3.2 Local audit... 4 4 Supporting Work Initiatives... 5 4.1 Identification
More informationNational Prostate Cancer Audit. Bill Cross June 2015
National Prostate Cancer Audit Bill Cross June 2015 National Prostate Cancer Audit aim of assessing the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales National
More informationThe Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 11, 2015
The Canadian National System for Incident Reporting in Radiation Treatment (NSIR-RT) Taxonomy March 11, 2015 Taxonomy Data Category Number Description Data Fields and Menu Choices 1. Impact 1.1 Incident
More informationWork Programme/Service Delivery Plan 2010/2013
Essex and East Suffolk Gynaecological Cancer Network Site Specific Group Work Programme/Service Delivery Plan 2010/2013 Version Number 1.2 Author Members of the NSSG Date Written June 2010 Reviewed May
More informationOvarian Cancer Quality Performance Indicators
Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official
More informationCancer Outcomes and Services Dataset: Implications for clinical teams
Cancer Outcomes and Services Dataset: Implications for clinical teams Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Consultant & Senior Lecturer in Respiratory Medicine,
More informationBreast Cancer Services in Ireland
Breast Cancer Services in Ireland European Commission Joint Research Centre, Ispra March 14 th 2013 Dr Jerome Coffey MD, FRCPI, FRCR, FFR RCSI Radiation Oncology Advisor on behalf of Dr Susan O Reilly
More informationHaemato-oncology Clinical Forum. 20 th June 2013
Haemato-oncology Clinical Forum 20 th June 2013 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair Purpose of today Provide an update on progress of the LCA to date Identify priorities for
More informationNatasha Baker Radiation Therapist
Natasha Baker Radiation Therapist This Presentation Give an overview of the information given to patients having radiation therapy at Palmerston North hospital To share the approach we have used in improving
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationWales Cancer Patient Experience. Survey Aneurin Bevan University Health Board. Published January 2014
Wales Cancer Patient Experience Survey 2013 Aneurin Bevan University Health Published January 2014 The Wales Cancer Patient Experience Survey was undertaken by Quality Health on behalf of the Welsh Government
More informationGUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE. Version:
GUIDELINES FOR RADIOTHERAPY IN SPINAL CORD COMPRESSION THE CHRISTIE, GREATER MANCHESTER & CHESHIRE Procedure Reference: Document Owner: Dr V. Misra Version: Accountable Committee: V4 Acute Oncology Group
More informationSpinal cord compression: what it means and how it can be treated
Spinal cord compression: what it means and how it can be treated Patient Information Oncology Department Author ID: Acute Oncology Nurse Specialist Leaflet Number: CC 036 Version: 2.1 Name of Leaflet:
More informationUpper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012
Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012 Version Control This is a controlled document please destroy all previous versions on receipt
More informationAn Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence
An Integrated National Strategy for Breast Cancer Audit Martin Lee Gill Lawrence National Audit Funding DH (NCAPOP* budget) Oversight National Clinical Audit Advisory Group (NCAAG) Commissioning and Monitoring
More informationSouth West Regional Cancer Program. Cancer Plan
South West Regional Cancer Program Cancer Plan 2016-2019 1. Cancer System Planning Cancer Care Ontario s role as the government s cancer advisor includes the development and implementation of a provincial
More informationAudit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017
Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical
More informationWhat are we aiming for?
The Priorities for Cancer Services Stephen Parsons Director What are we aiming for? Our aspiration is that England should achieve cancer outcomes which are comparable with the best in the world 1 Outline
More informationUrological cancers why we need to change. Stakeholder workshop 14 March 2013
Urological cancers why we need to change Stakeholder workshop 14 March 2013 Introduction and welcome Today s event aims to cover: 1. Background, clinical evidence and London Cancer s recommendations Q&As
More informationUpper GI Cancer Quality Performance Indicators
Publication Report Upper GI Cancer Quality Performance Indicators Patients diagnosed during January 2013 to December 2015 Publication date 28 th March 2017 An Official Statistics Publication for Scotland
More informationIdentifying and counting people living with treatable but not curable cancer
Identifying and counting people living with treatable but not curable cancer Rachel White Joanna Pethick, Archie Macnair, Gregory Fallica, Jennifer Than and Jane Maher September 2018 Who are the people
More informationImproving Outcomes for People with Sarcoma
NHS National Institute for Health and Clinical Excellence Guidance on Cancer Services Improving Outcomes for People with Sarcoma List of All Recommendations March 2006 Developed for NICE by the National
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationNational Cancer Patient Experience Programme. 2012/13 National Survey. East Kent Hospitals University NHS Foundation Trust. Published August 2013
National Cancer Patient Experience Programme 2012/13 National Survey Published August 2013 The National Cancer Patient Experience Survey Programme is being undertaken by Quality Health on behalf of NHS
More informationPathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer
NICaN Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer Timed schedules to enable the proactive management of the patient from point of receipt of referral to first definitive treatment
More informationMSCC CARE PATHWAYS & CASE STUDIES. By Michael Balloch Spine CNS
MSCC CARE PATHWAYS & CASE STUDIES By Michael Balloch Spine CNS Aims To be familiar with the routes of MSCC prentaion How the guidelines work in practice Routes of presentation Generic intervention Managing
More informationUnited Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report
United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report 20 June 2018 UKIACR Performance Indicators 2018 report 1 Contents Introduction... 3 Commentary for
More informationNational Cancer Programme. Work Plan 2015/16
National Cancer Programme Work Plan 2015/16 Citation: Ministry of Health. 2015. National Cancer Programme: Work plan 2015/16. Wellington: Ministry of Health. Published in October 2015 by the Ministry of
More informationANNUAL CANCER DELIVERY ACTION PLAN REPORT
AGENDA ITEM 6.4 6 May 2014 ANNUAL CANCER DELIVERY ACTION PLAN REPORT Executive Lead: Medical Director Author: UHB Cancer Lead Clinician/Cancer Lead Manager Contact Details for further information: Maggie
More informationNational Cancer Patient Experience Survey Results. Milton Keynes University Hospital NHS Foundation Trust. Published July 2016
National Cancer Patient Experience Survey 2015 Results Milton Keynes University Hospital NHS Foundation Trust Published July 2016 The National Cancer Patient Experience Survey is undertaken by Quality
More informationNational Cancer Peer Review Programme. Radiotherapy Service Evidence Guide
National Cancer Peer Review Programme Radiotherapy Service Evidence Guide Forward This evidence guide has been formulated to assist organisations in preparing for peer review. The contents of this guide
More informationSUBSPECIALIST TRAINING PROGRAMME
EUROPEAN BOARD AND COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS (EBCOG) AND EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY (ESGO) SUBSPECIALIST TRAINING PROGRAMME IN GYNAECOLOGICAL ONCOLOGY This Programme
More informationRadiotherapy Equipment Needs and Workforce Implications Cancer Services Co-ordinating Group
Radiotherapy Equipment Needs and Workforce Implications 2006-2016 Cancer Services Co-ordinating Group Radiotherapy & Chemotherapy Advisory Group May 2006 Acknowledgements The CSCG Radiotherapy and Chemotherapy
More informationAcute Oncology Martin Eatock Consultant Medical Oncologist NICaN Medical Director
Acute Oncology 2014 Martin Eatock Consultant Medical Oncologist NICaN Medical Director Patients admitted with cancer have a longer than average stay Berger et al. Clin Medicine (2013) Questions If your
More informationCancer and Data in the New NHS May Di Riley, Director Clinical Outcomes
Cancer and Data in the New NHS May 2011 Di Riley, Director Clinical Outcomes Overarching NHS context Financial constraints White Paper GP Commissioning/Commissioning Board Public Health England National
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More informationCancer Services Position & Recovery Plan June 2015
Appendix 6 Cancer Services Position & Recovery Plan June 2015 Introduction The Trust is required to achieve 85% compliance for patients on a 62 day pathway from the referral date to the date they receive
More informationLung Cancer Case Study
Lung Cancer Case Study Presented by s GP Education Programme 2 Part One Initial presentation 60 year old lady, presents with a 6 week history of right sided chest pain. The pain is like a dull ache, but
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy (IMRT) of Abdomen and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis
More informationEarly detection and prevention of lymphoedema
Early detection and prevention of lymphoedema Katie Riches Senior Research Nurse Derby Hospitals NHSF Trust Background: Derby Lymphoedema Service Three lymphoedema services based in Acute Hospitals at
More informationGuidelines for the Management of Suspected Sarcoma in Primary Care
Guidelines for the Management of Suspected Sarcoma in Primary Care Author: Anglia Cancer Network Sarcoma SSG Document Approved Date: 16-Dec-10 Review Date: December 2012 Ref Code: AngCN-SSG-Sa1 Status:
More informationT his article is based on a recent report from
62 EFFECTIVENESS BULLETIN A systematic review of cancer waiting time audits R Lewis, R Collins, A Flynn, M Emmans Dean, L Myers, P Wilson, A Eastwood... A summary of a systematic review of clinical audits
More informationWHERE NEXT FOR CANCER SERVICES IN NORTHERN IRELAND? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN NORTHERN IRELAND? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected
More informationMasDA Mastectomy Decisions Audit 2015
MasDA Mastectomy Decisions Audit 2015 AUDIT PROTOCOL FULL TITLE Mastectomy Decisions Audit: a prospective, multi-centre, population-based audit SHORT TITLE MasDA CHIEF INVESTIGATORS Mrs Jagdeep K Singh,
More informationRecommendations for cross-sectional imaging in cancer management, Second edition
www.rcr.ac.uk Recommendations for cross-sectional imaging in cancer management, Second edition Carcinoma of unknown primary origin (CUP) Faculty of Clinical Radiology www.rcr.ac.uk Contents Carcinoma of
More informationActivity Report April 2012 to March 2013
North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor
More informationThe Future of the Peer Review Programme
The Future of the Peer Review Programme The future of the programme has been in some considerable doubt. However thanks to the support of: Sean Duffy National Clinical Lead for Cancer, James Palmer Clinical
More informationWorking Group on Cancer Services
21 st November 2016 Working Group on Cancer Services A meeting of the Working Group on Cancer Services was held on 3 rd November 2016 at 11am, The Royal College of Pathologists, 4th Floor, 21 Prescot Street,
More informationNational Cancer Patient Experience Survey Results. University Hospitals of Leicester NHS Trust. Published July 2016
National Cancer Patient Experience Survey 2015 Results University Hospitals of Leicester NHS Trust Published July 2016 Revised 17th August 2016 The National Cancer Patient Experience Survey is undertaken
More information